<DOC>
	<DOCNO>NCT03018080</DOCNO>
	<brief_summary>The primary objective study assess safety feasibility follow two regimen : Cohort A ) phase regimen pembrolizumab paclitaxel follow paclitaxel plus pembrolizumab Cohort B ) concurrent regimen paclitaxel plus pembrolizumab . The primary safety objective evaluate overall grade 3 4 treatment-related adverse event rate cohort compare relevant historical control .</brief_summary>
	<brief_title>Pilot Study Paclitaxel Plus Pembrolizumab Metastatic HER2-Negative Breast Cancer</brief_title>
	<detailed_description>This open-label randomized pilot research study determine study drug , pembrolizumab , safe use combination chemotherapy drug call paclitaxel . This study follow two regimen : Cohort A ) phase regimen pembrolizumab paclitaxel follow paclitaxel plus pembrolizumab Cohort B ) concurrent regimen paclitaxel plus pembrolizumab . A total 40 evaluable subject enrol enrollment period 18-24 month . The study plan enroll approximately 20 evaluable subject treatment cohort .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet following criterion : 1 . Histologically cytological confirm diagnosis HER2negative metastatic breast cancer locally advance disease amenable resection . Available ER PR status tumor sample either hormone receptor positive negative tumor . For subject hormone receptorpositive , HER2negative metastatic breast cancer , eligible already receive intolerant least two line endocrine therapy , appropriate candidate chemotherapy ( large burden visceral disease ) . 2 . Measurable disease RECIST 1.1 , evaluable bone disease , i.e. , bone lesion lytic mixed ( lytic sclerotic ) absence measurable lesion . 3 . Male female age 18 year age old . 4 . ECOG performance status 0 , 1 2 . 5 . Must normal organ marrow function define : Hematologic Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 75,000/mcL Hemoglobin ≥ 9 g/dL Renal Creatinine ≤ 1.5X ULN Measured calculate creatinine clearance ( CrCl ) ≥ 30 mL/min subject creatinine level &gt; 1.5X ULN ( CrCl calculate per institutional standard ; GFR also use place creatinine CrCl ) Hepatic Total bilirubin ≤ 1.5X ULN subject total bilirubin level &gt; 1.5X ULN , direct bilirubin ≤ULN AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5X ULN Coagulation PT PTT ≤ 1.5X ULN ; subject receive anticoagulant therapy eligible PT PTT within therapeutic range intend use anticoagulant per investigator discretion . INR ≤ 1.5 ; Patients receive anticoagulant therapy eligible INR stable within recommended range desire level anticoagulation per investigator discretion . 6 . Female subject childbearing potential must negative serum urine pregnancy test within 14 day prior receive C1D1 . 7 . Female subject childbearing potential must willing use adequate method birth control , surgically sterile , abstain heterosexual activity course study 120 day last dose study therapy . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Male subject reproductive potential agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . Abstinence acceptable establish preferred contraception subject . 8 . Available tumor tissue newly obtain core excisional biopsy metastatic tumor lesion . For locally advanced disease , biopsy breast tumor regional area acceptable . Recently obtain tissue collect within 8 week prior treatment Cycle 1 , Day 1 acceptable . Note : Subjects tumor biopsy newly obtain ( i.e . inaccessible tumor subject safety concern ) may submit archived tumor specimen primary tumor metastatic biopsy collect within 6 month consent . 9 . Ability understand willingness sign write informed consent document . Exclusion Criteria Subjects must meet following criterion : 1 . Prior chemotherapy within 3 week , prior target small molecule therapy radiation therapy within 2 week , prior anticancer monoclonal antibody direct antineoplastic treatment within 4 week prior Cycle 1 Day 1 . 2 . Not recover ( i.e . ≤ Grade 1 ) adverse event due agent previously administer . Note : Subjects ≤ Grade 2 neuropathy alopecia grade exception may qualify study . 3 . More three prior line chemotherapy metastatic disease locally advanced disease amenable resection . Note : NonChemotherapy regimens count prior line ( example , hormonals , biologics ) 4 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent agent direct another coinhibitory Tcell receptor ( e.g . CTLA4 , OX40 , CD137 ) participate Merck MK3475 trial ( ) . 5 . Has major surgery within 3 week prior Cycle 1 Day 1 . 6 . Has receive investigational agent within 4 week Cycle 1 Day 1 study therapy . 7 . Known active uncontrolled symptomatic central nervous system ( CNS ) metastases and/or carcinomatous meningitis indicate clinical symptom , cerebral edema , and/or progressive growth . Note : Subjects treat CNS metastasis eligible asymptomatic , requirement steroid , requirement anticonvulsant , stable CNS radiographic study show significant vasogenic edema ≥ 4 week since completion radiation ≥ 2 week since discontinuation steroid . 8 . History know allergic reaction paclitaxel 9 . Has history current evidence condition , therapy , laboratory abnormality might interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 10 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial treatment . Pregnant woman exclude study paclitaxel agent potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother paclitaxel , breastfeed discontinue mother treated paclitaxel . These potential risk also apply pembrolizumab use study . 11 . Has know history Human Immunodeficiency Virus ( HIV ) know acquired immunodeficiency disorder ( AIDS ) . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction paclitaxel pembrolizumab . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . 12 . Has know active infection hepatitis B hepatitis C. 13 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( i.e. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 14 . Has know additional malignancy progress require active treatment within last 5 year . Note : Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy , situ cervical cancer . 15 . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . 16 . Has active infection require systemic therapy . 17 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 18 . Has receive live vaccine within 30 day Cycle 1 Day 1 study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however , intranasal influenza vaccine ( e.g. , FluMist ) live attenuate vaccine , allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>